Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the safe duration of therapy for patients infected with HCV genotype 6?

Nature Clinical Practice Gastroenterology & Hepatology volume 6, pages 78–79 (2009)Cite this article

Abstract

Very few studies have been published on response to treatment and treatment duration of patients infected with HCV genotype 6. This commentary discusses a study by Nguyen et al. that confirms that standard therapy is associated with a high-virologic response in patients infected with HCV genotype 6. This study also reported that patients who had chronic HCV infection with genotype 6 had a higher rate of sustained virologic response to 48 weeks of treatment with pegylated interferon plus ribavirin than to 24 weeks of treatment with the same combination of drugs. Although these results are promising, they need to be validated in a large prospective study before general conclusions can be drawn.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  CAS  Google Scholar 

  2. Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965

    Article  CAS  Google Scholar 

  3. Zeuzem S et al. (2004) Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 and 3. J Hepatol 40: 993–999

    Article  CAS  Google Scholar 

  4. Ferenci P et al. (2008) Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135: 451–458

    Article  CAS  Google Scholar 

  5. Nguyen MH et al. (2008) Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 103: 1131–1135

    Article  CAS  Google Scholar 

  6. Hui CK et al. (2003) Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 187: 1071–1074

    Article  CAS  Google Scholar 

  7. Dev AT et al. (2002) Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 36: 1259–1265

    Article  Google Scholar 

  8. Fung J et al. (2008) Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 198: 808–812

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. N Antaki is the Chief of the Department of Gastroenterology and Hepatology of the Saint Louis Hospital in Aleppo, Syrian Arab Republic.,

    Nabil Antaki

  2. P Marcellin is Head of the Viral Hepatitis Research Unit and INSERM U773-CRB3 at the Beaujon Hospital in Clichy, France.,

    Patrick Marcellin

Authors
  1. Nabil Antaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Marcellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil Antaki.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antaki, N., Marcellin, P. What is the safe duration of therapy for patients infected with HCV genotype 6?. Nat Rev Gastroenterol Hepatol 6, 78–79 (2009). https://doi.org/10.1038/ncpgasthep1335

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep1335

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing